Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10825883 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL6941525 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL10826161 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL3488296 | 0.98 | TSHR (0.56) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL31018369 | 0.96 | L3MBTL1 (0.51) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL31018373 | 0.94 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL1001167 | 0.92 | TSHR (0.58) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL14673059 | 0.91 | TSHR (0.48) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL14673427 | 0.91 | TSHR (0.48) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL14673320 | 0.91 | TSHR (0.48) | L3MBTL1TDP1TSHRHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5565526-A | Functionalized initiators for anionic polymerization | FMC CORPORATION (US) | 1996-10-15 | — | — | US | claimed |
| US-10351643-B2 | Polymerizable compounds, compositions, polymers, optically anisotropic articles, liquid crystal display devices and organic EL devices | DIC CORPORATION (JP) | 2019-07-16 | — | — | US | disclosed |
| US-20170037159-A1 | POLYMERIZABLE COMPOUNDS, COMPOSITIONS, POLYMERS, OPTICALLY ANISOTROPIC ARTICLES, LIQUID CRYSTAL DISPLAY DEVICES AND ORGANIC EL DEVICES | DIC CORPORATION (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170037159-A1 | POLYMERIZABLE COMPOUNDS, COMPOSITIONS, POLYMERS, OPTICALLY ANISOTROPIC ARTICLES, LIQUID CRYSTAL DISPLAY DEVICES AND ORGANIC EL DEVICES | DIC CORPORATION (JP) | 2017-02-09 | — | — | US | disclosed |
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| EP-0827423-B1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORP (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| EP-0873990-A1 | BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0827423-A1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORPORATION (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5708092-A | Functionalized chain extended initiators for anionic polymerization | FMC CORPORATION (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0749466-B1 | NOVEL POLYMERISABLE LIQUID-CRYSTALLINE COMPOUNDS | BASF AG (DE) | 1997-11-12 | — | — | EP | disclosed |
| US-5654371-A | Anionic polymerization process using functionalized initiators | FMC CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| CN-1143973-A | Novel polymerisable liquid-crystalline compounds | BASF AG (DE) | 1997-02-26 | — | — | CN | disclosed |
| EP-0749466-A1 | NOVEL POLYMERISABLE LIQUID-CRYSTALLINE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996035509-A1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORPORATION (US) | 1996-11-14 | — | — | WO | disclosed |
| US-5565526-A | Functionalized initiators for anionic polymerization | FMC CORPORATION (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1995024454-A1 | NOVEL POLYMERISABLE LIQUID-CRYSTALLINE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037159-A1 | POLYMERIZABLE COMPOUNDS, COMPOSITIONS, POLYMERS, OPTICALLY ANISOTROPIC ARTICLES, LIQUID CRYSTAL DISPLAY DEVICES AND ORGANIC EL DEVICES | LASP1, ILK, LAS1L | L3MBTL1 1288/4885TDP1 2603/4885TSHR 4831/4885 |
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | L3MBTL1 483/4885TDP1 1253/4885TSHR 2624/4885 |
| US-10351643-B2 | Polymerizable compounds, compositions, polymers, optically anisotropic articles, liquid crystal display devices and organic EL devices | LASP1, ILK, LAS1L | L3MBTL1 1298/4885TDP1 2607/4885TSHR 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.